Elsevier

Heart Failure Clinics

Volume 8, Issue 3, July 2012, Pages 301-317
Heart Failure Clinics

Classification of Pulmonary Hypertension

https://doi.org/10.1016/j.hfc.2012.04.013Get rights and content

Introduction

Pulmonary hypertension (PH) is a condition of many causes in which there is an elevation in pulmonary artery pressure (PAP) that results from an increase in:

  • 1.

    Resistance to blood flow within the pulmonary arteries (ie, pulmonary vascular resistance [PVR])

  • 2.

    Pulmonary blood flow

  • 3.

    Pulmonary venous pressure from left-sided heart failure (LHF)

  • 4.

    A combination of any of these 3 elements.

There is growing interest in PH among many medical specialists including cardiologists, pulmonologists, and rheumatologists, likely because of the current availability of specific drugs approved to treat a group of rare conditions defined as pulmonary arterial hypertension (PAH). The similarity between the terms “pulmonary hypertension” and “pulmonary arterial hypertension” has led to confusion and ambiguity in both clinical practice and the medical literature. Therefore, it is important to clarify the different hemodynamic definitions and the clinical classification of PH that, along with a complete diagnostic evaluation, lead to a final clinical diagnosis. The proper clinical diagnosis of PH is important because management of PH is dependent upon the underlying etiology and therapies that are effective in treating PAH may be detrimental when used inappropriately to treat other causes of PH.

Section snippets

Hemodynamic classification of pulmonary hypertension

PH is defined hemodynamically by invasive right heart catheterization (RHC) as a mean pulmonary artery pressure (mPAP) greater than 25 mm Hg. Formerly, PH was also diagnosed if the mPAP reached greater than 30 mm Hg during exercise; however, the exercise criterion was eliminated during the fourth World Symposium on PH because it was not supported by published data, and healthy individuals can reach higher levels of PAP.1, 2

In hemodynamic terms, PH related to increased PVR of 3.0 Wood units (WU)

Clinical classification of pulmonary hypertension

The clinical classification system for PH continues to evolve as our understanding of the pathologic basis of the various diseases that underlie the syndrome improves. The classification of PH has undergone a series of changes since it was first proposed in 1973.14

The initial classification designated only 2 categories: primary pulmonary hypertension (PPH) or secondary PH, depending on the presence or absence of identifiable causes or risk factors. Twenty-five years later (1998), the second

Summary

PH can develop in association with many different diseases and risk factors, and its presence is nearly always associated with reduced survival. Medical management of PH is largely dependent on its underlying etiology, and the combination of clinical and hemodynamic classifications of PH provides a framework for the diagnostic evaluation of PH to establish a final clinical diagnosis, and to guide therapy. The classification system for PH will continue to evolve as our understanding of the

First page preview

First page preview
Click to open first page preview

References (165)

  • E.B. Rosenzweig et al.

    Clinical implications of determining BMPR2 mutation status in a large cohort of children and adults with pulmonary arterial hypertension

    J Heart Lung Transplant

    (2008)
  • A.M. Walker et al.

    Temporal trends and drug exposures in pulmonary hypertension: an American experience

    Am Heart J

    (2006)
  • G. Simonneau et al.

    Primary pulmonary hypertension associated with the use of fenfluramine derivatives

    Chest

    (1998)
  • P.H. Schaiberger et al.

    Pulmonary hypertension associated with long-term inhalation of “crank” methamphetamine

    Chest

    (1993)
  • L.T. Wu et al.

    Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths

    Drug Alcohol Depend

    (2006)
  • K.M. Chin et al.

    Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?

    Chest

    (2006)
  • T.W. Bunch et al.

    Pulmonary hypertension in polymyositis

    Chest

    (1981)
  • K.K. Kim et al.

    Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome

    Hum Pathol

    (1987)
  • S. Almodovar et al.

    Pulmonary hypertension associated with HIV infection: pulmonary vascular disease: the global perspective

    Chest

    (2010)
  • N.J. Mehta et al.

    HIV-Related pulmonary hypertension: analytic review of 131 cases

    Chest

    (2000)
  • S. Cicalini et al.

    Pulmonary hypertension and human immunodeficiency virus infection: epidemiology, pathogenesis, and clinical approach

    Clin Microbiol Infect

    (2011)
  • J. Kim et al.

    HIV envelope protein gp120 induces neuropeptide Y receptor-mediated proliferation of vascular smooth muscle cells: relevance to AIDS cardiovascular pathogenesis

    Regul Pept

    (1998)
  • A. Hadengue et al.

    Pulmonary hypertension complicating portal hypertension: prevalence and relation to splanchnic hemodynamics

    Gastroenterology

    (1991)
  • M.J. Krowka et al.

    Portopulmonary hypertension: a report from the US-based REVEAL registry

    Chest

    (2012)
  • M.G. Duffels et al.

    Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry

    International journal of cardiology

    (2007)
  • C.J. dos Santos Fernandes et al.

    Survival in schistosomiasis-associated pulmonary arterial hypertension

    J Am Coll Cardiol

    (2010)
  • P. Steinmann et al.

    Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk

    Lancet Infect Dis

    (2006)
  • R.F. Machado et al.

    Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective

    Chest

    (2010)
  • S.A. Stayer et al.

    Pulmonary hypertension of the newborn

    Best Pract Res Clin Anaesthesiol

    (2010)
  • D. Montani et al.

    Pulmonary veno-occlusive disease: recent progress and current challenges

    Respir Med

    (2010)
  • M. Guglin et al.

    Pulmonary hypertension in heart failure

    J Card Fail

    (2010)
  • M.M. Hoeper et al.

    Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension

    J Am Coll Cardiol

    (2009)
  • C.S. Lam et al.

    Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study

    J Am Coll Cardiol

    (2009)
  • F. Bursi et al.

    Pulmonary pressures and death in heart failure: a community study

    J Am Coll Cardiol

    (2012)
  • I. Ben-Dor et al.

    Clinical profile, prognostic implication, and response to treatment of pulmonary hypertension in patients with severe aortic stenosis

    Am J Cardiol

    (2011)
  • J. Kjaergaard et al.

    Prognostic importance of pulmonary hypertension in patients with heart failure

    Am J Cardiol

    (2007)
  • S. Ghio et al.

    Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure

    J Am Coll Cardiol

    (2001)
  • F. Grigioni et al.

    Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure

    J Heart Lung Transplant

    (2006)
  • K.K. Khush et al.

    Effect of pulmonary hypertension on clinical outcomes in advanced heart failure: analysis of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) database

    Am Heart J

    (2009)
  • G. Kovacs et al.

    Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review

    Eur Respir J

    (2009)
  • R. Naeije et al.

    Mechanisms of improved arterial oxygenation after peripheral chemoreceptor stimulation during hypoxic exercise

    J Appl Phys

    (1993)
  • K. Chatterjee et al.

    Pulmonary hypertension: hemodynamic diagnosis and management

    Arch Intern Med

    (2002)
  • M.H. Drazner et al.

    The relationship of right- and left-sided filling pressures in patients with heart failure and a preserved ejection fraction

    Circ Heart Fail

    (2010)
  • S.V. Abramson et al.

    Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy

    Ann Intern Med

    (1992)
  • E. Braunwald et al.

    Effects of mitral-valve replacement on the pulmonary vascular dynamics of patients with pulmonary hypertension

    N Engl J Med

    (1965)
  • S. Hatano et al.

    Primary pulmonary hypertension. Report on a WHO meeting

    (1975)
  • G. Simonneau et al.

    Clinical classification of pulmonary hypertension

    J Am Coll Cardiol

    (2004)
  • M. Humbert et al.

    Pulmonary arterial hypertension in France: results from a national registry

    Am J Respir Crit Care Med

    (2006)
  • S. Rich et al.

    Primary pulmonary hypertension. A national prospective study

    Ann Intern Med

    (1987)
  • A. Chaouat et al.

    Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension

    Thorax

    (2004)
  • Cited by (7)

    • Two-pore channels mediated receptor-operated Ca<sup>2+</sup> entry in pulmonary artery smooth muscle cells in response to hypoxia

      2018, International Journal of Biochemistry and Cell Biology
      Citation Excerpt :

      Exploring pathological changes in PA remodeling and contractility is a key for PAH (Kuhr et al., 2012; Stenmark and Rabinovitch, 2010). It is well known that chronic hypoxia contribute to pH by enhancing proliferation and contractility of PASMC as well as intracellular Ca2+ ([Ca2+]i) level (Kuhr et al., 2012; Mcglothlin, 2012; Pak et al., 2007). The biological mechanism for the correlations between hypoxia and PAH has been actively explored in both animal models and cell culture systems for several decades.

    • BDNF secretion by human pulmonary artery endothelial cells in response to hypoxia

      2014, Journal of Molecular and Cellular Cardiology
      Citation Excerpt :

      Accordingly, enhanced vascular tone as occurs with diseases such as pulmonary hypertension represents, at least in part, an imbalance between vasoconstriction vs. vasodilation [1–4]. In this regard, factors such as hypoxia that are known to induce and exacerbate pulmonary hypertension [5–7] can target pulmonary artery endothelial cells (PAECs) and therefore exacerbate their dysfunction. However, the mechanisms by which hypoxia affects PAECs are still under investigation.

    • Pulmonary hypertension in ckd: A new problem child

      2015, Cardio-Renal Clinical Challenges
    View all citing articles on Scopus
    View full text